切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2023, Vol. 17 ›› Issue (01) : 1 -8. doi: 10.3877/cma.j.issn.1674-0793.2023.01.001

所属专题: 指南共识

专家共识

结直肠癌靶向治疗中国专家共识
中国医师协会结直肠肿瘤专业委员会, 中国抗癌协会大肠癌专业委员会, 国家癌症中心国家肿瘤质控中心结直肠癌质控专家委员会   
  • 收稿日期:2022-09-02 出版日期:2023-02-01

Chinese expert consensus on targeted therapy for colorectal cancer

Colorectal Cancer Committee of Chinese Medical Doctor Association, Colorectal Cancer Professional Committee of Chinese Anti-Cancer Association, Expert Committee on Quality Control of Colorectal Cancer of Center National Cancer/National Cancer Quality Control Center   

  • Received:2022-09-02 Published:2023-02-01
引用本文:

中国医师协会结直肠肿瘤专业委员会, 中国抗癌协会大肠癌专业委员会, 国家癌症中心国家肿瘤质控中心结直肠癌质控专家委员会. 结直肠癌靶向治疗中国专家共识[J]. 中华普通外科学文献(电子版), 2023, 17(01): 1-8.

Colorectal Cancer Committee of Chinese Medical Doctor Association, Colorectal Cancer Professional Committee of Chinese Anti-Cancer Association, Expert Committee on Quality Control of Colorectal Cancer of Center National Cancer/National Cancer Quality Control Center. Chinese expert consensus on targeted therapy for colorectal cancer[J]. Chinese Archives of General Surgery(Electronic Edition), 2023, 17(01): 1-8.

近年来,随着新型靶向药物的应用,靶向治疗已成为结直肠癌个体化治疗和综合治疗的一线方案,中国医师协会结直肠肿瘤专业委员会、中国抗癌协会大肠癌专业委员会以及国家癌症中心国家肿瘤质控中心结直肠癌质控专家委员会组织全国多位专家,讨论了结直肠肿瘤靶向药物的规范应用。

In recent years, with the application of new targeted drugs, it has become a first-line scheme for individualized and comprehensive treatment of colorectal cancer. Colorectal Cancer Committee of Chinese Medical Doctor Association, Colorectal Cancer Professional Committee of Chinese Anti-Cancer Association, Expert Committee on Quality Control of Colorectal Cancer of Center National Cancer/National Cancer Quality Control Center organized many experts nationwide to discuss the standardized application of colorectal cancer targeted drugs.

[1]
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9.
[2]
Ferlay J, Ervik M, Lam F, et al. Global cancer observatory: cancer today[DB/OL]. Lyon, France: International Agency for Research on Cancer. accessed[15032020].

URL    
[3]
Beppu T, Emi Y, Tokunaga S, et al. Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study)[J]. Anticancer Res, 2014, 34(11): 6655-6662.
[4]
Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014[J]. CA Cancer J Clin, 2014, 64(1): 9-29.
[5]
王延召, 雷福明. 结直肠癌靶向药物治疗[J]. 实用临床医学, 2016, 17(3): 101-103.
[6]
姜帅, 蔡晧东, 董梅. 应重视对新型抗肿瘤药物不良反应的监测[J].药物不良反应杂志, 2020, 22(4): 217-220.
[7]
Fuchs CS, Tomasek J, Yong CJ, et al. REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): An international, randomised, multicentre, placebo-controlled, phase 3 trial[J]. Lancet, 2014, 383(9911): 31-39.
[8]
Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): A double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(11): 1224-1235.
[9]
Strumberg D, Schultheis B. Regorafenib for cancer[J]. Expert Opin Investig Drugs, 2012, 21(6): 879-889.
[10]
Roper J, Sinnamon MJ, Coffee EM, et al. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wildtype, KRAS mutant colorectal cancer[J]. Cancer Lett, 2014, 347: 204-211.
[11]
Kim D, Xue JY, Lito P. Targeting KRAS(G12C): from inhibitory mechanism to modulation of antitumor effects in patients[J]. Cell, 2020, 183(4): 850-859.
[12]
Hong DS, Fakih MG, Strickler JH, et al. KRASG12C inhibition with sotorasib in advanced solid tumors[J]. N Engl J Med, 2020, 383(13): 1207-1217.
[13]
Jones JC, Renfro LA, Al-Shamsi HO, et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer[J]. J Clin Oncol, 2017, 35(23): 2624-2630.
[14]
Ward RL, Hicks S, Hawkins NJ. Population-based molecular screening for Lynch syndrome: implications for personalized medicine[J]. J Clin Oncol, 2013, 31(20): 2554-2562.
[15]
Jiang W, Cai MY, Li SY, et al. Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: high prevalence and unique molecular features[J]. Int J Cancer, 2019, 144(9): 2161-2168.
[16]
Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer[J]. Cancer Cell, 2018, 33(1): 125-136, e3.
[17]
Sartore-Bianchi A, Amatu A, Porcu L, et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer[J]. Oncologist, 2019, 24(10): 1395-1402.
[18]
Sartore-Bianchi A, Trusolino L, Martino C, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): A proof-of-concept, multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(6): 738-746.
[19]
Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): An updated report from a multicentre, open-label, phase 2a, multiple basket study[J]. Lancet Oncol, 2019, 20(4): 518-530.
[20]
Guo Y, Guo XL, Wang S, et al. Genomic alterations of NTRK, POLE, ERBB2, and microsatellite instability status in Chinese patients with colorectal cancer[J]. Oncologist, 2020, 5(11): e1671-e1680.
[21]
Wang H, Li ZW, Ou Q, et al. NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability[J]. Cancer Med, 2022, 11(13): 2541-2549.
[22]
Wollina U. Update of cetuximab for non-melanoma skin cancer[J].Expert Opin Biol Ther, 2014, 14(2): 271-276.
[1] 代莉, 邓恢伟, 郭华静, 黄芙蓉. 术中持续输注艾司氯胺酮对腹腔镜结直肠癌手术患者术后睡眠质量的影响[J]. 中华普通外科学文献(电子版), 2023, 17(06): 408-412.
[2] 张华, 孙宇, 乡世健, 李樱媚, 王小群. 循环肿瘤细胞预测晚期胃肠癌患者化疗药物敏感性的研究[J]. 中华普通外科学文献(电子版), 2023, 17(06): 422-425.
[3] 王得晨, 杨康, 杨自杰, 归明彬, 屈莲平, 张小凤, 高峰. 结直肠癌微卫星稳定状态和程序性死亡、吲哚胺2,3-双加氧酶关系的研究进展[J]. 中华普通外科学文献(电子版), 2023, 17(06): 462-465.
[4] 唐旭, 韩冰, 刘威, 陈茹星. 结直肠癌根治术后隐匿性肝转移危险因素分析及预测模型构建[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 16-20.
[5] 张生军, 赵阿静, 李守博, 郝祥宏, 刘敏丽. 高糖通过HGF/c-met通路促进结直肠癌侵袭和迁移的实验研究[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 21-24.
[6] 莫波, 王佩, 王恒, 何志军, 梁俊, 郝志楠. 腹腔镜胃癌根治术与改良胃癌根治术治疗早期胃癌的疗效[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 644-647.
[7] 李婷, 张琳. 血清脂肪酸代谢物及维生素D水平与结直肠癌发生的关系研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 661-665.
[8] 索郎多杰, 高红桥, 巴桑顿珠, 仁桑. 腹腔镜下不同术式治疗肝囊型包虫病的临床疗效分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 670-673.
[9] 唐浩, 梁平, 徐小江, 曾凯, 文拨辉. 三维重建指导下腹腔镜右半肝加尾状叶切除治疗Bismuth Ⅲa型肝门部胆管癌的临床研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 688-692.
[10] 关旭, 王锡山. 基于外科与免疫视角思考结直肠癌区域淋巴结处理的功与过[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 448-452.
[11] 顾睿祈, 方洪生, 蔡国响. 循环肿瘤DNA检测在结直肠癌诊治中的应用与进展[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 453-459.
[12] 邰清亮, 施波, 侍新宇, 陈国梁, 陈俊杰, 武冠廷, 王索, 孙金兵, 顾闻, 叶建新, 何宋兵. 腹腔镜次全结肠切除术治疗顽固性慢传输型便秘的疗效分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 478-483.
[13] 倪文凯, 齐翀, 许小丹, 周燮程, 殷庆章, 蔡元坤. 结直肠癌患者术后发生延迟性肠麻痹的影响因素分析[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 484-489.
[14] 范小彧, 孙司正, 鄂一民, 喻春钊. 梗阻性左半结肠癌不同手术治疗方案的选择应用[J]. 中华结直肠疾病电子杂志, 2023, 12(06): 500-504.
[15] 钟广俊, 刘春华, 朱万森, 徐晓雷, 王兆军. MRI联合不同扫描序列在胃癌术前分期诊断及化疗效果和预后的评估[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 378-382.
阅读次数
全文


摘要